At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 67 enrolled
Drug / intervention
Quinagolide 1080 µg +1 moredrug
Likely dose
Quinagolide 1080 µgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomised, Double-blind, Placebo-controlled, Proof-of-mechanism Phase 2 Trial Investigating the Effect of Quinagolide Extended-release Vaginal Ring on Reduction of Lesions Assessed by High-resolution Magnetic Resonance Imaging in Women With Endometrioma, Deep Infiltrating Endometriosis, and/or Adenomyosis
In Brief
A Phase 2 clinical trial evaluating Quinagolide 1080 µg and Placebo for Endometriosis. Completed, enrolled 67 participants across 11 sites in 4 countries.
Detailed Summary
This will be a randomized, double-blind, placebo-controlled, proof-of-mechanism phase 2 trial investigating the effect of quinagolide extended-release vaginal ring on reduction of lesions assessed by high-resolution magnetic resonance imaging in women with endometrioma, deep infiltrating endometriosis, and/or adenomyosis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEndometriosis
CountriesDenmark, Germany, Italy, Poland
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedNov 2018
Enrollment StartAug 2019
Primary CompletionJun 2021
Study CompletionJul 2021
TodayJul 2026
First PostedNov 21, 2018
Enrollment StartAug 19, 2019
Primary CompletionJun 21, 2021
Study CompletionJul 18, 2021
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 7.6 years ago
Interventions
Quinagolide 1080 µgdrug
Vaginal ring containing Quinagolide 1080 µg for daily releases
Placebodrug
Matching placebo